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International guidelines define a BK virus (BKV) load of ≥4 log10 copies/ml as
presumptive of BKV-associated nephropathy (BKVN) and a cutoff for therapeutic
intervention. To investigate whether BKV DNA loads (BKVL) are comparable
between laboratories, 2 panels of 15 and 8 clinical specimens (urine, whole blood,
and plasma) harboring different BKV genotypes were distributed to 20 and 27
French hospital centers in 2013 and 2014, respectively. Although 68% of the
reported results fell within the acceptable range of the expected result ±0.5 log10,
the interlaboratory variation ranged from 1.32 to 5.55 log10. Polymorphisms
specific to BKV genotypes II and IV, namely, the number and position of mutations
in amplification target genes and/or deletion in standards, arose as major sources of
interlaboratory disagreements. The diversity of DNA purification methods also
contributed to the interlaboratory variability, in particular for urine samples. Our
data strongly suggest that (i) commercial external quality controls for BKVL
assessment should include all major BKV genotypes to allow a correct evaluation of
BKV assays, and (ii) the BKV sequence of commercial standards should be provided
to users to verify the absence of mismatches with the primers and probes of their
BKV assays. Finally, the optimization of primer and probe design and
standardization of DNA extraction methods may substantially decrease
interlaboratory variability and allow interinstitutional studies to define a universal
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